BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:N-dihydrogalactochitosan readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of N-dihydrogalactochitosan\, from ClinicalT
 rials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06630624-2292@assetmemo.bio
DTSTAMP:20261121T005737Z
DTSTART;VALUE=DATE:20290801
DTEND;VALUE=DATE:20290802
SUMMARY:N-dihydrogalactochitosan: Phase 1/2 readout est. (NCT06630624)
DESCRIPTION:N-dihydrogalactochitosan\, phase 1/2\, Colorectal Cancer.\nStud
 y: Dose Finding\, Efficacy and Immunological Response of IP-001 Following 
 MWA or IRE for CRLM\nEstimated primary completion: 1 August 2029. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/n-dihydrogalactochitosan#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06630624
URL:https://assetmemo.bio/drug/n-dihydrogalactochitosan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06526338-2292@assetmemo.bio
DTSTAMP:20261121T005737Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:N-dihydrogalactochitosan: Phase 2 readout est. (NCT06526338)
DESCRIPTION:N-dihydrogalactochitosan\, phase 2.\nStudy: Adjuvant IP-001 Tre
 atment for HCC Patients Following Surgical Resection and Ablation or Ablat
 ion Alone\nEstimated primary completion: December 2029. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/n-dihydrogalactochitosan#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06526338
URL:https://assetmemo.bio/drug/n-dihydrogalactochitosan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07930936-2292@assetmemo.bio
DTSTAMP:20261121T005737Z
DTSTART;VALUE=DATE:20300101
DTEND;VALUE=DATE:20300102
SUMMARY:N-dihydrogalactochitosan: Phase 1 readout est. (NCT07930936)
DESCRIPTION:N-dihydrogalactochitosan\, phase 1.\nStudy: Immunotherapy and I
 rreversible Electroporation (IRE) in the Treatment of Locally Advanced Pan
 creatic Adenocarcinoma\nEstimated primary completion: 1 January 2030. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/n-dihydrogalactochitosan#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0793
 0936
URL:https://assetmemo.bio/drug/n-dihydrogalactochitosan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07321847-2292@assetmemo.bio
DTSTAMP:20261121T005737Z
DTSTART;VALUE=DATE:20331231
DTEND;VALUE=DATE:20340101
SUMMARY:N-dihydrogalactochitosan: Phase 2/3 readout est. (NCT07321847)
DESCRIPTION:N-dihydrogalactochitosan\, phase 2/3\, Colorectal Cancer.\nStud
 y: Injection of IP-001 Into Thermally Ablated Hepatic Tumors in Patients W
 ith Colorectal Liver Metastases\nEstimated primary completion: December 20
 33. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/n-dihydrogalactoc
 hitosan#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07321847
URL:https://assetmemo.bio/drug/n-dihydrogalactochitosan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
